Ramipril detailed information
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 28% |
| Protein binding | 73% (ramipril) 56% (ramiprilat) |
| Metabolism | Hepatic, to ramiprilat |
| Elimination half-life | 2 to 4 hours |
| Excretion | Renal (60%) and fecal (40%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C23H32N2O5 |
| Molar mass | 416.511 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
For patient information, click here
Overview
Ramipril (marketed as Tritace/Ramace or Altace) is an angiotensin-converting enzyme (ACE) inhibitor, used to treat hypertension and congestive heart failure. ACE inhibitors lower the production of angiotensin II, therefore relaxing arterial muscles while at the same time enlarging the arteries, allowing the heart to pump blood more easily, and increasing blood flow due to more blood being pumped into and through larger passageways.
Ramipril is a prodrug and is converted to the active metabolite ramiprilat by liver esterase enzymes. Ramiprilat is mostly excreted by the kidneys. The half-life of ramiprilat is variable (3-16 hours), and is prolonged by heart and liver failure, as well as kidney failure.
Indications
Indications for its use include:
- Mild to moderate hypertension;
- Congestive heart failure;
- Following myocardial infarction in patients with clinical evidence of heart failure;
- Susceptible patients over 55 years: prevention of myocardial infarction, stroke, cardiovascular death or need of revascularization procedures.
- Also ramipril has been known to be abused as a downer
Cautions
- Do not take potassium supplements without seeking medical advice.
- Do not take during pregnancy
Contraindications
Renovascular disease, severe renal impairment (especially in patients with one kidney or with bilateral renal artery stenosis), volume-depleted patients, history of angioedema while on an ACE inhibitor, pregnancy, hypotension.
Side-effects
- may cause swelling of the mouth, tongue, or throat
- low blood sugar in patients taking other medicine for diabetes which shows as sweating or shakiness
- persistent dry cough, dizziness, and light-headedness due to low blood pressure.
Dose
- 2.5 to 20 mg per day
- initial dose of 1.25mg per day
See also
External links
- Altace (ramipril), a registered trademark of King Pharmaceuticals, Inc.